Research programme: zidovudine stem cell therapeutics - ZGene/Karolinska Institute

Drug Profile

Research programme: zidovudine stem cell therapeutics - ZGene/Karolinska Institute

Latest Information Update: 09 Oct 2014

Price : $50

At a glance

  • Originator Karolinska Institute; ZGene
  • Class Cell therapies
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Cancer pharmacodynamics section
  • 29 Mar 2004 Preclinical trials in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top